Skip to main content
. 2023 Feb 16;28:249–263. doi: 10.1016/j.omto.2023.02.004

Figure 1.

Figure 1

Design, in vitro expression, and binding assessment of EGFRvIII-DBTE

(A) Design and structure of EGFRvIII-DBTE. (B) Western blot using supernatant of Expi293F cells transfected with EGFRvIII-DBTE or pVAX1 (vehicle control). (C) Flow cytometry data showing on-cell binding activities of EGFRvIII-DBTE to U87vIII cells and human T cells. HER2-DBTE was used as an isotype control. (D) Flow cytometry data showing T cell-bound U87vIII cells in the presence of EGFRvIII-DBTE. GFP is an EGFRvIII reporter. CD19-DBTE was used as an isotype control. (E) Microscopic images showing T cell clustering around the U87vIII cells in a tumor-killing assay (5-h incubation).